Upcoming Financial Results Schedules, Clinical Studies and Trials, and New Appointments - Research Report on BioMarin, Alnylam,

  Upcoming Financial Results Schedules, Clinical Studies and Trials, and New
  Appointments - Research Report on BioMarin, Alnylam, Aegerion, Omeros, and
                                    Tesaro

PR Newswire

NEW YORK, October 15, 2013

NEW YORK, October 15, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts Corner announced new research reports highlighting BioMarin
Pharmaceutical Inc. (NASDAQ: BMRN), Alnylam Pharmaceuticals, Inc. (NASDAQ:
ALNY), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Omeros Corporation
(NASDAQ: OMER), and Tesaro, Inc. (NASDAQ: TSRO). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

BioMarin Pharmaceutical Inc. Research Report

On October 10, 2013, BioMarin Pharmaceuticals Inc. (BioMarin) announced that
its CEO, Jean-Jacques Bienaimé, will host a conference call on October 24, at
5:00 p.m. ET to discuss Q3 2013 financial results. BioMarin reported that the
live audio webcast and its replay (archived on the site for one week following
the call) will be available on its website, under the investor section. The
Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/9b6c_BMRN]

--

Alnylam Pharmaceuticals, Inc. Research Report

On October 8, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that it
is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic
targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of hepatic
porphyrias including acute intermittent porphyria (AIP). The Company stated
that it expects to file an Investigational New Drug application for this RNAi
therapeutic in 2014. Rachel Meyers, Ph.D., Vice President of Research and RNAi
Lead Development at Alnylam, commented, "We are very pleased to advance
ALN-AS1 as a new Development Candidate in our 'Alnylam 5x15' pipeline, with
the goal of filing an IND in 2014. Our new pre-clinical data show that
subcutaneous administration of ALN-AS1 results in complete suppression of the
toxic heme biosynthesis intermediates that cause the symptoms and pathology of
AIP." The Full Research Report on Alnylam Pharmaceuticals, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/5b29_ALNY]

--

Aegerion Pharmaceuticals, Inc. Research Report

On October 10, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) announced that
it will host a conference call and live audio webcast on October 30, 2013 at
8:30 a.m. EDT to discuss its Q3 2013 financial and operational results and to
provide a business update. The Company stated that the call can be accessed
through its website under the "Investors" section. The call will also be
archived on Aegerion's website for 30 days after the call. The Full Research
Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/a3f6_AEGR]

--

Omeros Corporation Research Report

On October 8, 2013, Omeros Corporation (Omeros) announced the appointment of
Michael K. Inouye as Vice President of Commercial Operations. The Company
stated that Mr. Inouye has over 20 years of management experience in the
pharmaceutical industry, and has previously served as Senior Vice President,
Corporate and Commercial Development for Pharmacyclics, and Senior Vice
President, Commercial Operations at Telik. Commenting on the appointment,
Gregory A. Demopulos, M.D., Omeros' Chairman and CEO said, "With his deep
expertise in building commercial organizations and his proven track record of
successful drug-product launches, Mike is an important part of our team as we
prepare for and execute the 2014 planned launch of OMS302. Given his breadth
of experience, I expect that Mike will also play a key role in advancing the
rest of our pipeline toward commercialization." The Full Research Report on
Omeros Corporation - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/e3c9_OMER]

--

Tesaro, Inc. Research Report

On September 30, 2013, Tesaro, Inc. (Tesaro) announced that an open label,
dose-finding and escalation study has been initiated to evaluate the
pharmacokinetics, safety and tolerability of an intravenous (IV) formulation
of rolapitant in healthy volunteers. According to Tesaro, Rolapitant is an
investigational neurokinin-1 (NK-1) receptor antagonist in development for the
prevention of chemotherapy-induced nausea and vomiting (CINV). The Company
stated that the data from the Phase 1 study will be used to select the
intravenous dose that will be advanced into a subsequent clinical study. Mary
Lynne Hedley, Ph.D., President of Tesaro, said, "We are pleased to be
advancing both oral and IV formulations of rolapitant. Intravenous antiemetic
formulations comprise approximately 80% of the CINV market opportunity and
enable healthcare providers to ensure that their patients receive medication
to prevent chemotherapy-induced nausea and vomiting when administered
immediately prior to treatment." The Full Research Report on Tesaro, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/4258_TSRO]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.